DAA use decreases risk for cardiovascular events in patients with advanced fibrosis, HCV
LONDON — Direct-acting antiviral treatment correlated with a decreased risk for cardiovascular outcomes among patients with hepatitis C virus and advanced fibrosis but an increased…